NASDAQ:AVRO
AVROBIO Inc Stock News
$1.26
+0.0100 (+0.80%)
At Close: May 08, 2024
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
11:36am, Friday, 08'th May 2020
Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
Avrobio Magenta Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma
06:44pm, Thursday, 07'th May 2020
Avrobio and Magenta will collaborate on a novel ADC. Adverum reports positive wet AMD data. AstraZeneca's Farxiga is approved.
AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
11:00am, Thursday, 07'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended Mar
AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
12:00am, Thursday, 07'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today re
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Wednesday, 06'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory
AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel ta
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company, along with its academic
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a new development and commercialization ag
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
May 02, 2020 (CDN Newswire via Comtex) --
A recent comprehensive study titled Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market 2020...
Avrobio (AVRO) Gets a Buy Rating from Mizuho Securities
08:05am, Tuesday, 28'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO) today and set a price target of $35.00. The company's shares closed last
Avrobio (AVRO) Gets a Buy Rating from Mizuho Securities
08:05am, Tuesday, 28'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO – Research Report) today and set a price
Is AVROBIO (AVRO) Stock a Solid Choice Right Now?
12:58pm, Tuesday, 14'th Apr 2020
AVROBIO (AVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO
06:26pm, Sunday, 12'th Apr 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO
